Immune-mediated necrotizing myopathy associated with antibodies to hydroxy-methyl-glutaryl-coenzymeA reductase;Myopathie nécrosante auto-immune associée aux anticorps anti-hydroxy-méthyl-glutaryl-coenzyme A réductase

Revue de Medecine Interne

Volumn 35, Issue 8, 2014, Pages 546-549

  Hinschberger, O ^a   Lohmann, C ^a   Lannes, B ^b   Martzolff, L ^a   Vo, B D ^a   Jaeger Bizet, F ^a   Ciobanu, E ^a   Kieffer, P ^a  

^a Hôpitaux Universitaires de Strasbourg   (France)

^b Service de pathologie HÔpital de Hautepierre   (France)

Author keywords

Anti 3 hydroxy 3 methyl glutaryl coenzymeA reductase antibodies; Myotoxicity; Necrotizing myopathy; Statins

Indexed keywords

ANTIBODY; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR ANTIBODY; METHOTREXATE; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE NECROTIZING MYOPATHY; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; MIDDLE AGED; TOXIC MYOPATHY; TREATMENT DURATION; AUTOIMMUNE DISEASES; BLOOD; CHEMICALLY INDUCED; DRUG COMBINATION; IMMUNOLOGY; MUSCULAR DISEASES; NECROSIS; PATHOLOGY; RISK FACTOR; SKELETAL MUSCLE; TIME; TREATMENT OUTCOME;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DISEASES; NECROSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904215775     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2013.06.009     Document Type: Article

References (25)

1. Dimitri D., Eymard B. Myopathies inflammatoires, myopathies nécrosantes auto-immunes, myopathies génétiques de l'adulte: frontières diagnostiques. Rev Med Interne 2012, 33:134-142.
2. Allenbach Y., Benveniste O. Les myopathies nécrosantes acquises. Rev Med Interne 2013, 34:363-368.
3. Kostis W.J., Cheng J.Q., Dobrzynski J.M., Cabrera J., Kostis J.B. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012, 59:572-582.
4. Dalakas M.C. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009, 80:832-838.
5. Mastaglia F.L., Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012, 12:54-61.
6. Dieval C., Ribeiro E., Mercié P., Blanco P., Duffau P., Longy-Boursier M. Le syndrome des antisynthétases: étude rétrospective à propos d'une série de 14patients. Rev Med Interne 2012, 33:76-79.
7. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
8. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581-585.
9. Meriggioli M.N., Barboi A.C., Rowin J., Cochran E.J. HMG-CoA reductase inhibitor myopathy: clinical, electrophysiological, and pathologic data in five patients. J Clin Neuromuscul Disord 2001, 2:129-134.
10. Benveniste O., Drouot L., Jouen F., Charuel J.L., Bloch-Queyrat C., Behin A., et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011, 68:1961-1971.
11. Levin M.I., Mozaffar T., Al-Lozi M.T., Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998, 50:764-767.
12. Wegener S., Bremer J., Komminoth P., Jung H.H., Weller M. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. Case Rep Oncol 2010, 3:88-92.
13. Marie I., Boyer O. Myosites induites par les statines. Rev Med Interne 2013, 34:333-336.
14. Tomaszewski M., Stepień K.M., Tomaszewska J., Czuczwar S.J. Statin-induced myopathie. Pharmacol Rep 2011, 63:859-866.
15. El-Salem K., Ababneh B., Rudnicki S., Malkawi A., Alrefai A., Khader Y., et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011, 44:877-881.
16. Sathasivan S. Statin-induced myotoxicity. Eur J Intern Med 2012, 23:317-324.
17. Gabignon C., Zeller V., Le Guyader N., Desplaces N., Lidove O., Ziza J.M. Interaction atorvastatine et acide fusidique: une cause de rhabdomyolyse sévère. Rev Med Interne 2013, 34:39-41.
18. Tsivgoulis G., Spengos K., Karandreas N., Panas M., Kladi A., Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006, 166:1519-1524.
19. Mammen A.L., Pak K., Williams E.K., Brisson D., Coresh J., Selvin E., et al. Rarity of anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 2012, 64:269-272.
20. Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., et al. Autoantibodies against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63:713-721.
21. Christopher-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
22. Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185-190.
23. Padala S., Thompson P.D. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 2012, 222:15-21.
24. Sailler L., Pereira C., Bagheri A., Lapeyre-Mestre M., Montastruc J.L., Arlet P., et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 2008, 67:614-619.
25. Liang C., Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol 2011, 23:612-619.